Joon-Haeng Rhee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9104893/publications.pdf

Version: 2024-02-01

94 papers	6,082 citations	101496 36 h-index	74108 75 g-index
96 all docs	96 docs citations	96 times ranked	8555 citing authors

#	Article	IF	Citations
1	An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation. Biomaterials, 2022, 286, 121542.	5.7	10
2	Tumor Microenvironment-Regulating Immunosenescence-Independent Nanostimulant Synergizing with Near-Infrared Light Irradiation for Antitumor Immunity. ACS Applied Materials & Interfaces, 2021, 13, 4844-4852.	4.0	18
3	Solitary Fibrous Tumor/Hemangiopericytoma Metastasizes Extracranially, Associated with Altered Expression of WNT5A and MMP9. Cancers, 2021, 13, 1142.	1.7	6
4	Deimmunization of flagellin for repeated administration as a vaccine adjuvant. Npj Vaccines, 2021, 6, 116.	2.9	16
5	Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy. Cancers, 2021, 13, 4895.	1.7	11
6	Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Cells, 2020, 9, 2432.	1.8	34
7	DIDS inhibits Vibrio vulnificus cytotoxicity by interfering with TolC-mediated RtxA1 toxin secretion. European Journal of Pharmacology, 2020, 884, 173407.	1.7	3
8	Lipocalin2 Induced by Bacterial Flagellin Protects Mice against Cyclophosphamide Mediated Neutropenic Sepsis. Microorganisms, 2020, 8, 646.	1.6	6
9	Novel short peptide tag from a bacterial toxin for versatile applications. Journal of Immunological Methods, 2020, 479, 112750.	0.6	3
10	A stealth adhesion factor contributes to Vibrio vulnificus pathogenicity: Flp pili play roles in host invasion, survival in the blood stream and resistance to complement activation. PLoS Pathogens, 2019, 15, e1007767.	2.1	18
11	The cytochrome d oxidase complex regulated by fexA is an Achilles' heel in the in vivo survival of Vibrio vulnificus. Emerging Microbes and Infections, 2019, 8, 1406-1415.	3.0	1
12	A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma. Allergy, Asthma and Immunology Research, 2019, 11, 254.	1.1	12
13	Vibrio vulnificus RtxA1 cytotoxin targets filamin A to regulate PAK1- and MAPK-dependent cytoskeleton reorganization and cell death. Emerging Microbes and Infections, 2019, 8, 934-945.	3.0	10
14	A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases. Mucosal Immunology, 2019, 12, 565-579.	2.7	27
15	More robust gut immune responses induced by combining intranasal and sublingual routes for prime-boost immunization. Human Vaccines and Immunotherapeutics, 2018, 14, 2194-2202.	1.4	13
16	Vibrio vulnificus RtxA1 Toxin Expression Upon Contact With Host Cells Is RpoS-Dependent. Frontiers in Cellular and Infection Microbiology, 2018, 8, 70.	1.8	26
17	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. Frontiers in Immunology, 2018, 9, 1370.	2.2	49
18	Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Science Translational Medicine, 2017, 9, .	5.8	373

#	Article	IF	Citations
19	Mucosal immunization with a flagellin-adjuvanted Hgp44 vaccine enhances protective immune responses in a murine Porphyromonas gingivalis infection model. Human Vaccines and Immunotherapeutics, 2017, 13, 2794-2803.	1.4	12
20	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. Oncotarget, 2017, 8, 41538-41548.	0.8	39
21	Flagellin Modulates the Function of Invariant NKT Cells From Patients With Asthma via Dendritic Cells. Allergy, Asthma and Immunology Research, 2016, 8, 206.	1.1	6
22	Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression. Oncotarget, 2016, 7, 39894-39906.	0.8	32
23	All Three TonB Systems Are Required for Vibrio vulnificus CMCP6 Tissue Invasiveness by Controlling Flagellum Expression. Infection and Immunity, 2016, 84, 254-265.	1.0	17
24	Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. OncoImmunology, 2016, 5, e1081328.	2.1	29
25	Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells. Journal of Allergy and Clinical Immunology, 2016, 137, 426-435.	1.5	48
26	Characterization of Prohibitin 1 as a Host Partner ofVibrio vulnificusRtxA1 Toxin. Journal of Infectious Diseases, 2016, 213, 131-138.	1.9	17
27	Effects of Pyrogallol on Growth and Cytotoxicity of Wild-Type and katG Mutant Strains of Vibrio vulnificus. PLoS ONE, 2016, 11, e0167699.	1.1	14
28	Flagellinâ€dependent <scp>TLR</scp>5/caveolinâ€1 as a promising immune activator in immunosenescence. Aging Cell, 2015, 14, 907-915.	3.0	32
29	Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine. Clinical and Experimental Vaccine Research, 2015, 4, 59.	1.1	20
30	Safety and vaccine efficacy of an attenuatedVibrio vulnificusstrain with deletions in major cytotoxin genes. FEMS Microbiology Letters, 2015, 362, fnv169.	0.7	7
31	Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget, 2015, 6, 33781-33790.	0.8	27
32	In Vivo Efficacy of the Combination of Ciprofloxacin and Cefotaxime against Vibrio vulnificus Sepsis. PLoS ONE, 2014, 9, e101118.	1.1	20
33	Molecular characterization of vulnibactin biosynthesis in Vibrio vulnificus indicates the existence of an alternative siderophore. Frontiers in Microbiology, 2014, 5, 1.	1.5	1,166
34	DNA looping-dependent autorepression of LEE1 P1 promoters by Ler in enteropathogenic Escherichia coli (EPEC). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2586-95.	3.3	15
35	Contribution of Six Flagellin Genes to the Flagellum Biogenesis of Vibrio vulnificus and In Vivo Invasion. Infection and Immunity, 2014, 82, 29-42.	1.0	44
36	Mannose-poly(ethylene glycol)-linked SPION targeted to antigen presenting cells for magnetic resonance imaging on lymph node. Carbohydrate Polymers, 2013, 92, 1586-1595.	5.1	21

#	Article	IF	Citations
37	Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine, 2013, 31, 3879-3887.	1.7	75
38	A Bacterial RTX Toxin Causes Programmed Necrotic Cell Death Through Calcium-Mediated Mitochondrial Dysfunction. Journal of Infectious Diseases, 2013, 207, 1406-1415.	1.9	42
39	Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clinical and Experimental Vaccine Research, 2013, 2, 128.	1.1	16
40	Destructive Intestinal Translocation ofVibrio vulnificusDetermines Successful Oral Infection. Journal of Bacteriology and Virology, 2013, 43, 262.	0.0	1
41	Mucosal vaccine adjuvants update. Clinical and Experimental Vaccine Research, 2012, 1, 50.	1.1	117
42	Gene silencing by <scp><scp>Hâ€NS</scp></scp> from distal <scp>DNA</scp> site. Molecular Microbiology, 2012, 86, 707-719.	1.2	37
43	Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine, 2012, 30, 466-474.	1.7	69
44	Toll-Like Receptor Ligands as Cancer Immunotherapeutics. Journal of Bacteriology and Virology, 2012, 42, 255.	0.0	0
45	Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging. Carbohydrate Polymers, 2012, 87, 1159-1168.	5.1	22
46	Carboxylic mannan-coated iron oxide nanoparticles targeted to immune cells for lymph node-specific MRI in vivo. Carbohydrate Polymers, 2012, 88, 780-788.	5.1	27
47	Integrative genomeâ€scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Molecular Systems Biology, 2011, 7, 460.	3.2	157
48	Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine, 2011, 29, 5731-5739.	1.7	81
49	Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo. Acta Biomaterialia, 2011, 7, 3935-3945.	4.1	53
50	Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3088-3091.	1.0	35
51	Engineering and Visualization of Bacteria for Targeting Infarcted Myocardium. Molecular Therapy, 2011, 19, 951-959.	3.7	35
52	Immune response induced by ppGpp-defective Salmonella enterica serovar Gallinarum in chickens. Journal of Microbiology, 2010, 48, 674-681.	1.3	19
53	Crystal structure of the transcriptional activator HlyU from Vibrio vulnificus CMCP6. FEBS Letters, 2010, 584, 1097-1102.	1.3	18
54	RtxA1â€Induced Expression of the Small GTPase Rac2 Plays a Key Role in the Pathogenicity ofVibrio vulnificus. Journal of Infectious Diseases, 2010, 201, 97-105.	1.9	48

#	Article	IF	Citations
55	Generation of regulatory dendritic cells and CD4 ⁺ Foxp3 ⁺ T cells by probiotics administration suppresses immune disorders. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2159-2164.	3.3	527
56	Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Experimental and Molecular Medicine, 2010, 42, 407.	3.2	33
57	Outer membrane vesicles of Vibrio vulnificus deliver cytolysinâ€“hemolysin VvhA into epithelial cells to induce cytotoxicity. Biochemical and Biophysical Research Communications, 2010, 399, 607-612.	1.0	36
58	Suppressive Effects of Ginsan on the Development of Allergic Reaction in Murine Asthmatic Model. International Archives of Allergy and Immunology, 2009, 150, 32-42.	0.9	26
59	The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leukemia Research, 2009, 33, 665-670.	0.4	62
60	Protective effect of polygoni cuspidati radix and emodin on Vibrio vulnificus cytotoxicity and infection. Journal of Microbiology, 2008, 46, 737-743.	1.3	39
61	Vibrio vulnificus RTX toxin kills host cells only after contact of the bacteria with host cells. Cellular Microbiology, 2008, 10, 848-862.	1.1	168
62	Inhibition of Airway Allergic Disease by Co-Administration of Flagellin with Allergen. Journal of Clinical Immunology, 2008, 28, 157-165.	2.0	30
63	Stimulation by TLR5 Modulates Osteoclast Differentiation through STAT1/IFN-Î². Journal of Immunology, 2008, 180, 1382-1389.	0.4	47
64	Salmonella enterica Serovar Gallinarum Requires ppGpp for Internalization and Survival in Animal Cells. Journal of Bacteriology, 2008, 190, 6340-6350.	1.0	38
65	The pyrH Gene of Vibrio vulnificus Is an Essential In Vivo Survival Factor. Infection and Immunity, 2007, 75, 2795-2801.	1.0	39
66	Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leukemia and Lymphoma, 2007, 48, 2022-2031.	0.6	43
67	Vibrio vulnificusmetalloprotease VvpE is essentially required for swarming. FEMS Microbiology Letters, 2007, 269, 170-179.	0.7	34
68	Caenorhabditis elegans as a simple model host for Vibrio vulnificus infection. Biochemical and Biophysical Research Communications, 2006, 346, 751-757.	1.0	31
69	Crystal Structure and Functional Studies Reveal that PAS Factor from Vibrio vulnificus is a Novel Member of the Saposin-fold Family. Journal of Molecular Biology, 2006, 355, 491-500.	2.0	8
70	Vibrio vulnificus Vulnibactin, But Not Metalloprotease VvpE, Is Essentially Required for Iron-Uptake from Human Holotransferrin. Biological and Pharmaceutical Bulletin, 2006, 29, 911-918.	0.6	35
71	Proteomic analysis of pathogenic bacteriumVibrio vulnificus. Proteomics, 2006, 6, 1283-1289.	1.3	14
72	Effect of thecrpmutation on the utilization of transferrin-bound iron byVibrio vulnificus. FEMS Microbiology Letters, 2006, 257, 285-292.	0.7	28

#	Article	IF	Citations
73	A Bacterial Flagellin, Vibrio vulnificus FlaB, Has a Strong Mucosal Adjuvant Activity To Induce Protective Immunity. Infection and Immunity, 2006, 74, 694-702.	1.0	195
74	Aminoacyl-transferases and the N-end rule pathway of prokaryotic/eukaryotic specificity in a human pathogen. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3078-3083.	3.3	85
75	Swarming differentiation of vibrio vulnificus downregulates the expression of the vvhBA hemolysin gene via the LuxS quorum-sensing system. Journal of Microbiology, 2006, 44, 226-32.	1.3	10
76	Inactivation of Vibrio vulnificus Hemolysin by Oligomerization but Not Proteolysis. Biological and Pharmaceutical Bulletin, 2005, 28, 1294-1297.	0.6	14
77	Essential role of an adenylate cyclase in regulatingVibrio vulnificusvirulence. FEMS Microbiology Letters, 2005, 243, 497-503.	0.7	40
78	Vibrio vulnificusmetalloprotease VvpE has no direct effect on the iron-assimilation from human holotransferrin. FEMS Microbiology Letters, 2005, 247, 221-229.	0.7	14
79	DNA looping-mediated repression by histone-like protein H-NS: specific requirement of EÂ70 as a cofactor for looping. Genes and Development, 2005, 19, 2388-2398.	2.7	124
80	Vibrio parahaemolyticus Flagellin Stimulates the Maturation of Human Monocyte-Derived Dendritic Cells and Elicits Th1-Type Immune Response.. Blood, 2005, 106, 3872-3872.	0.6	0
81	ppGpp-dependent Stationary Phase Induction of Genes on Salmonella Pathogenicity Island 1. Journal of Biological Chemistry, 2004, 279, 34183-34190.	1.6	129
82	Production of Vibrio vulnificus hemolysin in vivo and its pathogenic significance. Biochemical and Biophysical Research Communications, 2004, 324, 86-91.	1.0	57
83	Factors influencing preferential utilization of RNA polymerase containing sigma-38 in stationary-phase gene expression in Escherichia coli. Journal of Microbiology, 2004, 42, 103-10.	1.3	21
84	Regulation of Vibrio vulnificus virulence by the LuxS quorum-sensing system. Molecular Microbiology, 2003, 48, 1647-1664.	1.2	214
85	Characterization and Pathogenic Significance of Vibrio vulnificus Antigens Preferentially Expressed in Septicemic Patients. Infection and Immunity, 2003, 71, 5461-5471.	1.0	259
86	Flagellar basal body flg operon as a virulence determinant of Vibrio vulnificus. Biochemical and Biophysical Research Communications, 2003, 304, 405-410.	1.0	66
87	Identification of thecadBAoperon fromVibrio vulnificusand its influence on survival to acid stress. FEMS Microbiology Letters, 2002, 208, 245-251.	0.7	58
88	CAS agar diffusion assay for the measurement of siderophores in biological fluids. Journal of Microbiological Methods, 2001, 44, 89-95.	0.7	135
89	Differential Expression of Vibrio vulnificus Elastase Gene in a Growth Phase-dependent Manner by Two Different Types of Promoters. Journal of Biological Chemistry, 2001, 276, 13875-13880.	1.6	64
90	Vibrio vulnificus Has the Transmembrane Transcription Activator ToxRS Stimulating the Expression of the Hemolysin GenevvhA. Journal of Bacteriology, 2000, 182, 3405-3415.	1.0	82

#	Article	IF	Citations
91	Construction and Phenotypic Evaluation of a Vibrio vulnificus vvpE Mutant for Elastolytic Protease. Infection and Immunity, 2000, 68, 5096-5106.	1.0	91
92	Evidence that Expression of the Vibrio vulnificus Hemolysin Gene Is Dependent on Cyclic AMP and Cyclic AMP Receptor Protein. Journal of Bacteriology, 1999, 181, 7639-7642.	1.0	34
93	Direct Identification of Vibrio vulnificus in Clinical Specimens by Nested PCR. Journal of Clinical Microbiology, 1998, 36, 2887-2892.	1.8	55
94	Vibrio vulnificus hemolysin dilates rat thoracic aorta by activating guanylate cyclase. Life Sciences, 1996, 59, PL41-PL47.	2.0	40